No significant difference between advanced therapies for RA

Individualised care should be based on clinical judgement and consideration of patient preferences. INTRODUCTION Rheumatoid arthritis is a chronic inflammatory disease that can affect a person’s joints, and may cause pain and disability. Rheumatoid arthritis affects people of all ages, and is more common in women than men. The goal of treatment is often remission […]

Read More…

TNF inhibitors help reduce the change of ankylosis as well as improve symptoms

Compared to other treatments, TNF inhibitors slowed radiologic progression significantly. INTRODUCTION Ankylosing spondylitis is a chronic inflammatory disease. It mainly affects the joints in the spine, and the sacroiliac joint (in the back part of the pelvis), causing back pain and stiffness. Some changes in ankylosing spondylitis are very slow. For example, the destruction of […]

Read More…

IL-17- or TNF inhibitors have comparable efficacy after failure of previous TNF inhibitors

Symptom relief and time on therapy are similar for people taking TNF inhibitors or secukinumab after previous TNF inhibitor failure. INTRODUCTION Spondyloarthritis (often shortened to SpA) is an umbrella term for several conditions that share many features and symptoms. These conditions include ankylosing spondylitis, psoriatic arthritis and reactive arthritis. Spondyloarthritis can be classified as axial […]

Read More…

Managing axial spondyloarthritis

This is the lay version of the EULAR recommendations for the management of people with axial spondyloarthritis. The original publication can be downloaded from the EULAR website: www.eular.org. van der Heijde D, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–991. doi:10.1136/annrheumdis-2016-210770 Introduction  EULAR recommendations give advice to […]

Read More…

Dose optimisation of TNF inhibitors results in considerable cost savings

TNF inhibitors are associated with long-term risks and high costs; improving how they are used is therefore important. INTRODUCTION Rheumatoid arthritis is a chronic inflammatory disease that affects a person’s joints and sometimes their internal organs, causing pain and disability. It is more common in older people, and affects both men and women. Adalimumab and […]

Read More…

Women with rheumatoid arthritis and those treated with TNF inhibitors may be at increased risk of cervical cancer

Women with rheumatoid arthritis have a higher risk of cervical cancer, and those treated with TNF inhibitors have a further increased risk, though the link is not conclusive. INTRODUCTION Rheumatoid arthritis is a chronic inflammatory disease that affects a person’s joints, causing pain and disability. It can also affect internal organs. Rheumatoid arthritis is more […]

Read More…

No additional risk of breast cancer recurrence with TNF inhibitors

Breast cancer survivors receiving TNF inhibitors for rheumatoid arthritis are not at an increased risk of their cancer recurring compared to those receiving other medicines. INTRODUCTION Rheumatoid arthritis is a chronic inflammatory disease that affects a person’s joints, causing pain and disability. It is more common in older people, and affects both men and women. […]

Read More…